NORML vs. The New York Times: The Latest Cannabis Media Fight

September 28, 2026

Photo by stevepb via Pixabay.

On September 16, 2026, NORML Deputy Director Paul Armentano published an op-ed, also syndicated through Cultivated News, taking direct aim at the New York Times' recent run of cannabis coverage. His argument boils down to two recurring anxieties he says the Times keeps recycling: today's marijuana is dangerously strong, and too many Americans are using it. Armentano doesn't just dispute the framing -- he lays out a case that the paper is cherry-picking data points to fit a predetermined narrative of alarm.

This isn't a one-off gripe. It's the third time in 2026 that NORML has publicly pushed back against the Times' cannabis reporting, following a February editorial rebuttal and a coordinated round of letters sent to three major national papers. Taken together, the pattern raises a question worth sitting with rather than rushing past: is this a genuine scientific disagreement over how to read ambiguous data, or is one newsroom running a consistent editorial thumb on the scale when it comes to marijuana? The honest answer, as usual, sits somewhere in between -- and the details matter more than the headlines on either side.

The Potency Panic Isn't New -- NORML Says the Times Has Been Here Before

Photo via Pexels.

Armentano's op-ed opens with a bit of archival digging that's genuinely useful context: a December 28, 1978 New York Times article headlined A More Potent Marijuana Is Stirring Fresh Debates. Read today, it sounds almost identical to 2026 coverage -- warnings about stronger flower, worried parents, calls for closer scrutiny. NORML's point is that this exact anxiety has been in circulation for nearly half a century, which suggests it's less a fresh discovery than a media rhythm that resurfaces every decade or so, dusted off whenever cultivation techniques or product formats change.

NORML's scientific counter to the potency panic rests on titration -- the well-documented tendency of cannabis consumers to adjust how much they use based on strength. Someone smoking 25% THC flower typically takes fewer, smaller hits than someone smoking 10% flower, aiming for the same subjective effect rather than getting proportionally more intoxicated. It's a reasonable behavioral argument, and it lines up with how people actually use alcohol, coffee, and other dose-adjustable substances.

But this is also where the op-ed leaves a gap. A 2026 cohort study using Danish national health registry data, published in JAMA Health Forum, found an association between rising availability of high-potency THC products and increased incidence of psychosis diagnoses over time. That's a serious, peer-reviewed data point, not tabloid speculation, and it doesn't fit neatly into a titration defense -- titration might reduce total intake, but it doesn't necessarily eliminate risk for people vulnerable to psychotic disorders at any dose. Armentano's op-ed doesn't engage with this research directly, which weakens the otherwise solid historical argument.

What the Cannabis Use Disorder Numbers Actually Show

Photo by Norman_Gil via Pixabay.

The numbers NORML and the Times are both citing come from the same federal drug use survey data. In 2024 data, nearly 7% of Americans age 12 and older met criteria for cannabis use disorder, with that figure climbing to nearly 16% among 18-to-25-year-olds. Those are real, government-collected numbers, and neither side disputes them. The fight is over what they mean.

NORML's argument, laid out in a companion piece Armentano published August 27, 2026, centers on how loose the diagnostic bar actually is. Under the current clinical criteria, a cannabis use disorder diagnosis requires meeting just 2 of 11 possible symptoms -- things like continuing to use despite a minor social conflict, or spending a fair amount of time thinking about cannabis. That threshold captures people with genuinely mild, low-impact patterns of use alongside people with severe, life-disrupting dependency, and lumping them into a single statistic makes the headline number look scarier than the underlying clinical picture.

NORML also flags a methodological wrinkle worth taking seriously: the diagnostic criteria for cannabis use disorder have been revised multiple times over the years, shifting thresholds and symptom lists in ways that make clean year-over-year comparisons genuinely shaky. A rising percentage could reflect more people struggling, or it could partly reflect a diagnostic net that's gotten wider.

This is really the crux of the entire scientific dispute. Nobody credible denies that reported cannabis use disorder rates have risen alongside legalization and higher-potency products. What's contested -- legitimately, by researchers on both sides -- is whether that rise represents a public health crisis or a statistical artifact of a low-specificity diagnostic tool applied to a much larger pool of legal users.

Youth Use Is Down, Not Up, Since Legalization

According to 2024 NSDUH data, young adults aged 18-25 have more than double the rate of cannabis use disorder (16%) compared to the overall population aged 12 and up (7%).

One of the more concrete, checkable claims in Armentano's op-ed is that adult-use legalization hasn't driven up youth cannabis consumption. This isn't spin -- it's consistent with data from long-running youth surveys, which have tracked teen marijuana use trending downward or flat since the first wave of recreational legalization began in Colorado and Washington, even as more states have joined in. Current teen use rates sit at or near historic lows going back decades.

That trend runs directly counter to the implication threaded through a lot of Times coverage: that wider legal access naturally means easier access for minors. NORML's response is that regulated markets actually work against that outcome, not for it. Licensed dispensaries check ID, face license revocation for selling to minors, and operate under compliance audits that illicit dealers simply don't answer to. A teenager trying to buy from a legal shop hits a hard wall; a teenager buying from an unregulated street source, or from an older sibling's illicit-market connection, doesn't.

There's a reasonable structural argument buried in here that goes beyond NORML's talking points: prohibition doesn't remove a product from a black market, it just removes the guardrails around who can access it. Legal markets, whatever their flaws, at least introduce an age-verification layer that unregulated markets never had to begin with.

None of this means youth access is a solved problem everywhere -- enforcement quality varies a lot by state, and some markets do a much better job policing ID checks than others. But the topline claim that legalization correlates with falling, not rising, teen use is well supported by the data NORML is citing, and it's a point that deserves more prominence in coverage that frames broader legal access as inherently risky for minors.

Why Alcohol Gets a Pass and Cannabis Doesn't

Photo via Pexels.

The sharpest part of Armentano's critique isn't about data at all -- it's about tone. He points to an August 3, 2026 Times piece, What Else Do We Lose When People Give Up Booze?, which acknowledged alcohol's well-documented harms -- liver disease, cancer risk, drunk driving deaths, a mortality burden that dwarfs cannabis by any measure -- but wrapped that acknowledgment in a wistful, almost elegiac tone about the social rituals and camaraderie fading along with declining drinking rates.

Compare that framing to how the same paper covers cannabis: potency warnings, disorder statistics, psychosis links, presented with little of the nostalgic hedging extended to alcohol. NORML's argument is that this isn't really about risk calibration at all, since alcohol's harm profile is worse by nearly every epidemiological measure that matters -- overdose deaths, hospitalizations, chronic disease burden. It's about which substance gets treated as a normal part of adult social life worth mourning a little, and which one gets treated as a menace worth warning people away from.

This is the fairness argument that sits at the center of a lot of NORML's advocacy work generally, not just this one op-ed: legal substances should be evaluated against consistent standards, using comparable evidence, rather than having editorial tone shift depending on which substance has been culturally normalized for longer. Whether or not the Times intended a double standard, the contrast between the two pieces is hard to read past once it's pointed out.

A Pattern of Pushback: NORML's Year of Fighting the Times

Photo via Unsplash.

This September op-ed doesn't exist in isolation -- it's the latest move in a running fight that's stretched across most of 2026. The opening shot came in February, when the Times ran an editorial titled It's Time for America to Admit That It Has a Marijuana Problem, calling for federal THC potency caps and effectively reversing the paper's own 2014 editorial that had endorsed legalization.

Armentano responded fast. A rebuttal letter ran in the Times itself on February 13, 2026, and NORML placed companion letters the same month in the Washington Post, headlined Cannabis is legitimate, and the Wall Street Journal, headlined Should we worry about teen cannabis use? -- a coordinated three-paper push rather than a single reply lobbed at one outlet.

The Times' editorial also drew support from the other direction. Conservative commentator Alex Berenson wrote a Fox News op-ed on February 18, 2026 praising the shift, leaning on his 2019 book Tell Your Children, which argues for a strong causal link between cannabis potency and psychosis. Berenson's work is contested among researchers too, but it gave the Times' editorial position a visible ally outside its own pages.

Seen end to end -- the February editorial fight, the letter-writing campaign, and now a September op-ed -- this looks less like NORML reacting to isolated articles and more like a deliberate, sustained media strategy aimed at one specific newsroom's editorial direction on cannabis. That's a notable shift in advocacy tactics, treating a single paper's coverage pattern as a target worth repeated, public correction rather than letting individual stories pass without response.

Strip away the tone on both sides and you're left with a genuinely messy scientific picture. The potency data is real. The rise in reported cannabis use disorder is real. The Danish psychosis research is real and peer-reviewed. None of that is fabricated or exaggerated by the Times. But NORML also has a legitimate point about selective framing -- alcohol's far larger mortality footprint doesn't get the same sensational treatment, and a diagnostic threshold requiring just two mild symptoms out of eleven is doing a lot of quiet work in headlines about an addiction epidemic. Where Armentano's op-ed falls short is in simply not addressing the psychosis-risk research at all, rather than making a case against it.

The responsible move for readers isn't picking a side based on which framing feels more comfortable. It's going to the primary sources directly -- the underlying survey tables, youth-use trend lines, the actual JAMA Health Forum paper -- rather than trusting either a newsroom's editorial slant or an advocacy group's counter-framing to summarize it fairly. Both blanket alarm and blanket dismissal are asking you to skip that step.

And none of this changes the practical reality that cannabis law, potency limits, and youth-access rules differ enormously from state to state and country to country. What's legal and lightly regulated in one place can carry real legal exposure in another. Whatever you make of the Times-versus-NORML fight, check your own jurisdiction's current rules before assuming a national media narrative, in either direction, tells you anything about the law where you actually live.